Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence
Technology in Cancer Research & Treatment · 2026
DOI: 10.1177/15330338261440434 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, 2026. Verfasst von Jun-Xian He und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Electronics and Communication Engineering, Guangzhou University, Guangzhou, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, Artificial Intelligence. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 243 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Li Ka-Shing Foundation at Shantou University Medical College, Li Ka-Shing Foundation STU-GTIIT Joint-research Grant.
Abstract (Originalsprache)
Management of metastatic prostate cancer (mPCa) poses significant challenges due to inherent tumor heterogeneity and therapeutic resistance. Advances in molecular imaging, liquid biopsies, and biomarkers are enabling precision oncology, while artificial intelligence (AI), including machine learning (ML) and deep learning (DL), integrates complex datasets to improve diagnostic accuracy, risk stratification, and treatment guidance. This review highlights AI’s applications in mPCa, focusing on imaging, cell-free nucleic acids, circulating tumor cells, and genomic classifiers. We emphasize AI’s role in enhancing diagnostics and personalizing treatments, with implications for improving clinical outcomes through better decision-making. Finally, we discuss opportunities and challenges in deploying AI systems, stressing multimodal integration and validation for real-world clinical impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Electronics and Communication Engineering, Guangzhou University, Guangzhou, China.
- Department of Medicine, North Alabama Medical Center, Florence, AL, USA.
- School of Computer Science and Cyber Engineering, Guangzhou University, Guangzhou, China.
- Clinical Pharmacology Section, Department of Pharmacology, Shantou University Medical College, Shantou, China.
- Department of Medical Education, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA.
ORCID-Profile: Luyuan Li, R Daniel Bonfil, Wensi Tao
Förderung
- National Natural Science Foundation of China
- Li Ka-Shing Foundation at Shantou University Medical College
- Li Ka-Shing Foundation STU-GTIIT Joint-research Grant
Zitieren
APA
He, J. X., Li, L., Chen, S., Chen, R. J., Zhuang, J. L., Liu, C., Burrow, W., Chang, J., Tanziela, T., Bonfil, R. D., Wong, N. K., & Tao, W. (2026). Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338261440434
Vancouver
He JX, Li L, Chen S, Chen RJ, Zhuang JL, Liu C, et al. Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence. Technology in Cancer Research & Treatment. 2026. doi:10.1177/15330338261440434
BibTeX
@article{He2026,
author = {He, Jun-Xian and Li, Luyuan and Chen, Shuhong and Chen, Rong-Jun and Zhuang, Jia-Le and Liu, Chang and Burrow, Wesley and Chang, Jonghoon and Tanziela, Tanziela and Bonfil, R Daniel and Wong, Nai-Kei and Tao, Wensi},
title = {Outsmarting Metastatic Prostate Cancer: Integration of Imaging, Liquid Biopsies and Biomarkers With Artificial Intelligence},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
doi = {10.1177/15330338261440434}
}
EUVIMED